Committee on Immunization Practices, 22337-22338 [2017-09707]

Download as PDF Federal Register / Vol. 82, No. 92 / Monday, May 15, 2017 / Notices or services to improve population health. Strongest consideration will be given to individuals with expertise and experience: • That is applied, with practical applications for public health action; • That addresses broad public health considerations, or is beyond one or two highly defined areas; and • In state and/or local health departments. In the current round of nominations, the strongest consideration will also be given to people with expertise and experience in systematic review methods, economic analysis, injury (in particular substance abuse and violence prevention), aging, and rural health. The CPSTF will also benefit from members with expertise and experience in the following areas: Minority health; worksite health; military health and readiness; and health media, communications and marketing. Candidates with experience and skills in any of these areas should highlight them in their nomination materials. All nominated individuals will be considered for CPSTF membership. Applicants must have no substantial conflicts of interest, whether financial, professional, or intellectual, that would impair the scientific integrity of the work of the CPSTF and must be willing to complete regular conflict of interest disclosures. Applicants must have the ability to work collaboratively with a team of diverse professionals who support the mission of the CPSTF. Applicants must have adequate time to contribute substantively to the work products of the CPSTF. jstallworth on DSK7TPTVN1PROD with NOTICES Nominee Selection Appointments to the CPSTF will be made on the basis of qualifications as outlined above (see Qualification Requirements) and the current expertise needs of the CPSTF. Time Commitment The CPSTF conducts three, two-day meetings each year that are open to the public. In addition, a significant portion of the CPSTF’s work occurs between meetings during conference calls and via email discussions. Member duties include overseeing the process of prioritizing Task Force work, participating in the development and refinement of systematic review methods, serving as members of individual review teams, and issuing recommendations and findings to help inform the decision making process about policy, practice, research, and research funding in a wide range of U.S. VerDate Sep<11>2014 13:51 May 12, 2017 Jkt 241001 settings. The estimated workload for CPSTF members is approximately 168 hours a year in addition to the three inperson meetings. The members are all volunteers and do not receive any compensation beyond support for travel to in-person meetings. Dated: May 10, 2017. Lauren Hoffmann, Acting Executive Secretary, Centers for Disease Control and Prevention. 22337 Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2017–09710 Filed 5–12–17; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2017–09733 Filed 5–12–17; 8:45 am] Centers for Disease Control and Prevention Advisory BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to PAR 13–129, Occupational Safety and Health Research, NIOSH Member Conflict Review. Times and Dates: 1:00 p.m.–4:00 p.m., EDT, June 8, 2017 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463. Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘NIOSH Member Conflict Review’’, PAR 13–129. Contact Person for More Information: Nina Turner, Ph.D., Scientific Review Officer, NIOSH, CDC, 1095 Willowdale Road, Mailstop G905, Morgantown, West Virginia 26506, Telephone: (304) 285–5976. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 Committee on Immunization Practices In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announce the following meeting of the aforementioned committee. Times and Dates: 8:30 a.m.–5:35 p.m., EDT, June 21, 2017 8:00 a.m.–1:00 p.m., EDT, June 22, 2017 Place: CDC, Tom Harkin Global Communications Center, 1600 Clifton Road NE., Building 19, Kent ‘‘Oz’’ Nelson Auditorium, Atlanta, Georgia 30329. Status: Open to the public, limited only by the space available. Time will be available for public comment. The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing by email to the contact person listed below. The deadline for receipt is June 12, 2017. All requests must contain the name, address, and organizational affiliation of the speaker, as well as the topic being addressed. Written comments should not exceed one singlespaced typed page in length and delivered in 3 minutes or less. Please note that the public comment period may end before the time indicated, following the last call for comments. Members of the public who wish to provide public comments should plan to attend the public comment session at the start time listed. Written comments received in advance of the meeting will be included in the official record of the meeting. The meeting will be webcast live via the World Wide Web; for instructions and more information on ACIP please visit the ACIP Web site: https:// www.cdc.gov/vaccines/acip/. Purpose: The committee is charged with advising the Director, CDC, on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to E:\FR\FM\15MYN1.SGM 15MYN1 22338 Federal Register / Vol. 82, No. 92 / Monday, May 15, 2017 / Notices vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under provisions of the Affordable Care Act, section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been approved by the Director of the Centers for Disease Control and Prevention and appear on CDC immunization schedules must be covered by applicable health plans. Matters for Discussion: The agenda will include discussions on: Meningococcal vaccine; influenza; hepatitis vaccines; herpes zoster vaccine; varicella; yellow fever vaccine; mumps disease and vaccine; Dengue virus vaccines; Human Papillomavirus (HPV); Anthrax vaccine workgroup; Vaccine Adverse Event Reporting System (VAERS) and vaccine supply. A recommendation vote is scheduled for hepatitis vaccines and influenza. A Vaccines for Children (VFC) vote is scheduled for hepatitis vaccines. Agenda items are subject to change as priorities dictate. ACIP Charter: https://www.cdc.gov/ vaccines/acip/committee/charter.html. Contact Person for More Information: Stephanie Thomas, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road NE., MS–A27, Atlanta, Georgia 30329, telephone 404/ 639–8836; Email ACIP@CDC.GOV. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2017–09707 Filed 5–12–17; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES jstallworth on DSK7TPTVN1PROD with NOTICES Centers for Disease Control and Prevention Interagency Committee on Smoking and Health: Notice of Charter Renewal This gives notice under the Federal Advisory Committee Act (Pub. L. 92– 463) of October 6, 1972, that the Interagency Committee on Smoking and Health, Department of Health and VerDate Sep<11>2014 13:51 May 12, 2017 Jkt 241001 Human Services, has been renewed for a 2-year period through March 20, 2019. For information, contact Simon McNabb, Designated Federal Officer, Interagency Committee on Smoking and Health, Centers for Disease Control and Prevention, Department of Health and Human Services, Patriot’s Plaza, 395 E Street SW., M/S P06, Washington, DC 20201, telephone 202/245–0550 or fax 202/245–0599, Email: BOL1@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2017–09709 Filed 5–12–17; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2017–D–2834] Three-Month Extension of Certain Tobacco Product Compliance Deadlines Related to the Final Deeming Rule; Guidance for Industry; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice of availability. [FR Doc. 2017–09708 Filed 5–12–17; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review The meeting announced below concerns the Centers for Disease Control and Prevention (CDC) initial review of applications in response to Funding Opportunity Announcement (FOA) TS17–001, Identify and Characterize Potential Environmental Risk Factors for Amyotrophic Lateral Sclerosis (ALS), TS17–001. Summary: This publication corrects a notice that was published in the Federal Register on May 4, 2017, Volume 82, No. 85, page 20895. The meeting time and date should read as follows: Time and Date: 8:00 a.m.–6:00 p.m., EST, June 14, 2017 (Closed). Contact Person for More Information: ´ Oscar Tarrago, M.D., M.P.H., Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F63, Atlanta, Georgia 30341, Telephone: (770) 488– 3492. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and PO 00000 Frm 00034 Fmt 4703 The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled ‘‘Three-Month Extension of Certain Tobacco Product Compliance Deadlines Related to the Final Deeming Rule.’’ This guidance is intended to assist persons who manufacture, package, sell, offer to sell, distribute, or import for sale and distribution within the United States newly regulated tobacco products, roll-your-own (RYO) tobacco, and cigarette tobacco in complying with the Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), and FDA regulations. SUMMARY: BILLING CODE 4163–18–P Sfmt 4703 Submit either electronic or written comments on Agency guidances at any time. ADDRESSES: You may submit comments as follows: DATES: Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or E:\FR\FM\15MYN1.SGM 15MYN1

Agencies

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention Advisory

[Federal Register Volume 82, Number 92 (Monday, May 15, 2017)]
[Notices]
[Pages 22337-22338]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-09707]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention Advisory


Committee on Immunization Practices

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announce the following meeting of the aforementioned 
committee.
    Times and Dates:

8:30 a.m.-5:35 p.m., EDT, June 21, 2017
8:00 a.m.-1:00 p.m., EDT, June 22, 2017

    Place: CDC, Tom Harkin Global Communications Center, 1600 Clifton 
Road NE., Building 19, Kent ``Oz'' Nelson Auditorium, Atlanta, Georgia 
30329.
    Status: Open to the public, limited only by the space available. 
Time will be available for public comment. The public is welcome to 
submit written comments in advance of the meeting. Comments should be 
submitted in writing by email to the contact person listed below. The 
deadline for receipt is June 12, 2017. All requests must contain the 
name, address, and organizational affiliation of the speaker, as well 
as the topic being addressed. Written comments should not exceed one 
single-spaced typed page in length and delivered in 3 minutes or less. 
Please note that the public comment period may end before the time 
indicated, following the last call for comments. Members of the public 
who wish to provide public comments should plan to attend the public 
comment session at the start time listed. Written comments received in 
advance of the meeting will be included in the official record of the 
meeting.
    The meeting will be webcast live via the World Wide Web; for 
instructions and more information on ACIP please visit the ACIP Web 
site: https://www.cdc.gov/vaccines/acip/.
    Purpose: The committee is charged with advising the Director, CDC, 
on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, 
the committee is mandated to establish and periodically review and, as 
appropriate, revise the list of vaccines for administration to

[[Page 22338]]

vaccine-eligible children through the Vaccines for Children (VFC) 
program, along with schedules regarding dosing interval, dosage, and 
contraindications to administration of vaccines. Further, under 
provisions of the Affordable Care Act, section 2713 of the Public 
Health Service Act, immunization recommendations of the ACIP that have 
been approved by the Director of the Centers for Disease Control and 
Prevention and appear on CDC immunization schedules must be covered by 
applicable health plans.
    Matters for Discussion: The agenda will include discussions on: 
Meningococcal vaccine; influenza; hepatitis vaccines; herpes zoster 
vaccine; varicella; yellow fever vaccine; mumps disease and vaccine; 
Dengue virus vaccines; Human Papillomavirus (HPV); Anthrax vaccine 
workgroup; Vaccine Adverse Event Reporting System (VAERS) and vaccine 
supply. A recommendation vote is scheduled for hepatitis vaccines and 
influenza. A Vaccines for Children (VFC) vote is scheduled for 
hepatitis vaccines.
    Agenda items are subject to change as priorities dictate.
    ACIP Charter: https://www.cdc.gov/vaccines/acip/committee/charter.html.
    Contact Person for More Information: Stephanie Thomas, National 
Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton 
Road NE., MS-A27, Atlanta, Georgia 30329, telephone 404/639-8836; Email 
ACIP@CDC.GOV.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities for 
both the Centers for Disease Control and Prevention and the Agency for 
Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2017-09707 Filed 5-12-17; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.